Bioasis Technologies Inc. V.BTI

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

TSXV:BTI - Post by User

Bioasis Technologies Inc. > This shows how the Financing Market is out there

<< Previous

Bullboard Posts

Next >>

Comment by craighenryon Dec 27, 2022 5:45pm

70 Views

Post# 35192854

RE:This shows how the Financing Market is out there

craighenry wrote: For many Biotech alike. Bioasis is no different.

"Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics"

This for Jounce shareholders is almost criminal.

Yes, before the resident but job mouths off, I know this has nothing to do with Bioasis.

My point is that DR probably had no other option other than to file C11.

There is not this big "conspiracy" that the nut job wants you to believe.

Link to the Gilead deal below:

https://www.stockwatch.com/News/Item/U-b20221227005077-U!JNCE-20221227/U/JNCE